NOBIPOL, Department of Biotechnology, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
Stem Cells Transl Med. 2017 Apr;6(4):1053-1058. doi: 10.1002/sctm.16-0116. Epub 2017 Feb 2.
Transplantation of pancreatic islets in immune protective capsules holds the promise as a functional cure for type 1 diabetes, also about 40 years after the first proof of principal study. The concept is simple in using semipermeable capsules that allow the ingress of oxygen and nutrients, but limit the access of the immune system. Encapsulated human islets have been evaluated in four small clinical trials where the procedure has been evaluated as safe, but lacking long-term efficacy. Host reactions toward the biomaterials used in the capsules may be one parameter limiting the long-term function of the graft in humans. The present article briefly discusses important capsule properties such as stability, permeability and biocompatibility, as well as possible strategies to overcome current challenges. Also, recent progress in capsule development as well as the production of insulin-producing cells from human stem cells that gives promising perspectives for the transplantation of encapsulated insulin-producing tissue is briefly discussed. Stem Cells Translational Medicine 2017;6:1053-1058.
胰岛移植在免疫保护胶囊中有望成为 1 型糖尿病的功能性治愈方法,这也是在首例主要研究 40 年后的成果。该概念使用半透性胶囊,允许氧气和营养物质进入,但限制免疫系统进入,其原理非常简单。已在四项小型临床试验中评估了包封的人胰岛,该程序已被评估为安全,但缺乏长期疗效。宿主对胶囊中使用的生物材料的反应可能是限制移植物在人体中长期功能的一个参数。本文简要讨论了胶囊的重要特性,如稳定性、渗透性和生物相容性,以及克服当前挑战的可能策略。此外,还简要讨论了胶囊开发的最新进展以及用人干细胞产生产生胰岛素的细胞,为包封的产生胰岛素的组织移植带来了有前景的视角。《干细胞转化医学》2017;6:1053-1058。